Click here to get full coverage on SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Yahoo Finance

SNGX: Important Upcoming Readouts in Phase 3 CTCL Study  Yahoo Finance

SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Yahoo Finance

Click here to get full coverage on Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - PR Newswire

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)  PR Newswire

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - PR Newswire

Click here to get full coverage on SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Smartkarma

SNGX: Important Upcoming Readouts in Phase 3 CTCL Study  Smartkarma

SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Smartkarma

Click here to get full coverage on SNGX: Positive Results for Phase 2a Trial in Psoriasis - Zacks Small Cap Research

SNGX: Positive Results for Phase 2a Trial in Psoriasis  Zacks Small Cap Research

SNGX: Positive Results for Phase 2a Trial in Psoriasis - Zacks Small Cap Research

Click here to get full coverage on SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Research Tree

SNGX: Important Upcoming Readouts in Phase 3 CTCL Study  Research Tree

SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Research Tree

Click here to get full coverage on Soligenix (SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behcet Disease - Yahoo Finance

Soligenix (SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behcet Disease  Yahoo Finance

Soligenix (SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behcet Disease - Yahoo Finance

Click here to get full coverage on Soligenix (SNGX) Leverages Platform Science for Broader Therapeutic Reach - Yahoo Finance

Soligenix (SNGX) Leverages Platform Science for Broader Therapeutic Reach  Yahoo Finance

Soligenix (SNGX) Leverages Platform Science for Broader Therapeutic Reach - Yahoo Finance

Click here to get full coverage on Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results - PR Newswire

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results  PR Newswire

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Soligenix Announces Closing of $7.5 Million Public Offering - PR Newswire

Soligenix Announces Closing of $7.5 Million Public Offering  PR Newswire

Soligenix Announces Closing of $7.5 Million Public Offering - PR Newswire

Click here to get full coverage on Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results - PR Newswire

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results  PR Newswire

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Soligenix Details Recent Progress and Upcoming Milestones - PR Newswire

Soligenix Details Recent Progress and Upcoming Milestones  PR Newswire

Soligenix Details Recent Progress and Upcoming Milestones - PR Newswire

Click here to get full coverage on Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma  PR Newswire

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire

Click here to get full coverage on Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis - PR Newswire

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis  PR Newswire

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis - PR Newswire

Click here to get full coverage on Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones - PR Newswire

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones  PR Newswire

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones - PR Newswire

Click here to get full coverage on Miami BIO summit to feature Soligenix CEO on rare disease drugs - Stock Titan

Miami BIO summit to feature Soligenix CEO on rare disease drugs  Stock Titan

Miami BIO summit to feature Soligenix CEO on rare disease drugs - Stock Titan

Click here to get full coverage on Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach - TradingView

Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach  TradingView

Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach - TradingView

Click here to get full coverage on Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - PR Newswire

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results  PR Newswire

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PR Newswire

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma  PR Newswire

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PR Newswire

Click here to get full coverage on Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky - Yahoo Finance

Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky  Yahoo Finance

Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky - Yahoo Finance

Click here to get full coverage on Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - Yahoo Finance

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space  Yahoo Finance

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - Yahoo Finance

Click here to get full coverage on Soligenix (SNGX) Receives UK Nod for Innovative Behcet's Disease Treatment - GuruFocus

Soligenix (SNGX) Receives UK Nod for Innovative Behcet's Disease Treatment  GuruFocus

Soligenix (SNGX) Receives UK Nod for Innovative Behcet's Disease Treatment - GuruFocus

Click here to get full coverage on $SNGX stock is down 20% today. Here's what we see in our data. - Quiver Quantitative

$SNGX stock is down 20% today. Here's what we see in our data.  Quiver Quantitative

$SNGX stock is down 20% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency - ChartMill

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency  ChartMill

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency - ChartMill

Click here to get full coverage on Soligenix Stock (SNGX) Opinions on Phase 3 HyBryte™ Safety Milestone - Quiver Quantitative

Soligenix Stock (SNGX) Opinions on Phase 3 HyBryte™ Safety Milestone  Quiver Quantitative

Soligenix Stock (SNGX) Opinions on Phase 3 HyBryte™ Safety Milestone - Quiver Quantitative

Click here to get full coverage on Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit - The Globe and Mail

Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit  The Globe and Mail

Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit - The Globe and Mail

Click here to get full coverage on SNGX: Multiple Catalysts Upcoming in 2H25… - Yahoo Finance

SNGX: Multiple Catalysts Upcoming in 2H25…  Yahoo Finance

SNGX: Multiple Catalysts Upcoming in 2H25… - Yahoo Finance

Click here to get full coverage on Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease - The Globe and Mail

Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease  The Globe and Mail

Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease - The Globe and Mail

Click here to get full coverage on SNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet’s Disease… - Yahoo Finance

SNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet’s Disease…  Yahoo Finance

SNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet’s Disease… - Yahoo Finance

Click here to get full coverage on Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease - Barchart.com

Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease  Barchart.com

Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease - Barchart.com

Click here to get full coverage on Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely - simplywall.st

Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely  simplywall.st

Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely - simplywall.st

Click here to get full coverage on Soligenix (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer - Digital Journal

Soligenix (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer  Digital Journal

Soligenix (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer - Digital Journal

Click here to get full coverage on Soligenix to Present at BIO Investment & Growth Summit - Quantisnow

Soligenix to Present at BIO Investment & Growth Summit  Quantisnow

Soligenix to Present at BIO Investment & Growth Summit - Quantisnow

Click here to get full coverage on New Behçet's Disease Drug Achieves 40% Improvement with Better Safety Profile than Otezla - Stock Titan

New Behçet's Disease Drug Achieves 40% Improvement with Better Safety Profile than Otezla  Stock Titan

New Behçet's Disease Drug Achieves 40% Improvement with Better Safety Profile than Otezla - Stock Titan

Click here to get full coverage on Soligenix (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology - Digital Journal

Soligenix (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology  Digital Journal

Soligenix (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology - Digital Journal

Click here to get full coverage on Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - PR Newswire

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results  PR Newswire

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - PR Newswire

Click here to get full coverage on Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - Digital Journal

Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach  Digital Journal

Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - Digital Journal

Click here to get full coverage on Why Is Soligenix Stock (SNGX) Up 50% Today? - TipRanks

Why Is Soligenix Stock (SNGX) Up 50% Today?  TipRanks

Why Is Soligenix Stock (SNGX) Up 50% Today? - TipRanks

Click here to get full coverage on Soligenix (SNGX) Stock Surges on FDA Orphan Drug Designation for Rare Disease Treatment – A Big Win for This Biotech Underdog - RagingBull

Soligenix (SNGX) Stock Surges on FDA Orphan Drug Designation for Rare Disease Treatment – A Big Win for This Biotech Underdog  RagingBull

Soligenix (SNGX) Stock Surges on FDA Orphan Drug Designation for Rare Disease Treatment – A Big Win for This Biotech Underdog - RagingBull

Click here to get full coverage on Soligenix stock tumbles after pricing $7.5 million public offering - Investing.com

Soligenix stock tumbles after pricing $7.5 million public offering  Investing.com

Soligenix stock tumbles after pricing $7.5 million public offering - Investing.com

Click here to get full coverage on Soligenix (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options - Digital Journal

Soligenix (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options  Digital Journal

Soligenix (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options - Digital Journal

Click here to get full coverage on Soligenix to Present at BIO Investment & Growth Summit (2026-02-24) - Seeking Alpha

Soligenix to Present at BIO Investment & Growth Summit (2026-02-24)  Seeking Alpha

Soligenix to Present at BIO Investment & Growth Summit (2026-02-24) - Seeking Alpha

Click here to get full coverage on Soligenix, Inc. Provides Shareholder Update on Clinical Progress and Financial Outlook - TradingView

Soligenix, Inc. Provides Shareholder Update on Clinical Progress and Financial Outlook  TradingView

Soligenix, Inc. Provides Shareholder Update on Clinical Progress and Financial Outlook - TradingView

Click here to get full coverage on SNGX Stock Price, News & Analysis - Stock Titan

SNGX Stock Price, News & Analysis  Stock Titan

SNGX Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on Soligenix receives Nasdaq notice for non-compliance with equity listing rule - Investing.com

Soligenix receives Nasdaq notice for non-compliance with equity listing rule  Investing.com

Soligenix receives Nasdaq notice for non-compliance with equity listing rule - Investing.com

Click here to get full coverage on Soligenix to Present at BIO Investment & Growth Summit - Nasdaq

Soligenix to Present at BIO Investment & Growth Summit  Nasdaq

Soligenix to Present at BIO Investment & Growth Summit - Nasdaq

Click here to get full coverage on Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape - Digital Journal

Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape  Digital Journal

Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape - Digital Journal

Click here to get full coverage on Why Soligenix Is Rising In Pre-market? - Nasdaq

Why Soligenix Is Rising In Pre-market?  Nasdaq

Why Soligenix Is Rising In Pre-market? - Nasdaq

Click here to get full coverage on Soligenix (NASDAQ: SNGX) Closes $7.5M Public Offering to Extend Cash Runway Through 2026 - Digital Journal

Soligenix (NASDAQ: SNGX) Closes $7.5M Public Offering to Extend Cash Runway Through 2026  Digital Journal

Soligenix (NASDAQ: SNGX) Closes $7.5M Public Offering to Extend Cash Runway Through 2026 - Digital Journal

Click here to get full coverage on Why SNGX Gains 8% Amid Positive Trends? - StocksToTrade

Why SNGX Gains 8% Amid Positive Trends?  StocksToTrade

Why SNGX Gains 8% Amid Positive Trends? - StocksToTrade

Click here to get full coverage on SNGX: Public Offering Raises 7.5 Million Expands European Medical Advisory Board - Smartkarma

SNGX: Public Offering Raises 7.5 Million Expands European Medical Advisory Board  Smartkarma

SNGX: Public Offering Raises 7.5 Million Expands European Medical Advisory Board - Smartkarma

Click here to get full coverage on Soligenix reports positive results from SGX945 Behçet’s trial - Investing.com

Soligenix reports positive results from SGX945 Behçet’s trial  Investing.com

Soligenix reports positive results from SGX945 Behçet’s trial - Investing.com

Click here to get full coverage on Soligenix expands European medical advisory board for lymphoma treatment - Investing.com

Soligenix expands European medical advisory board for lymphoma treatment  Investing.com

Soligenix expands European medical advisory board for lymphoma treatment - Investing.com

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Soligenix (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial - Digital Journal

Soligenix (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial  Digital Journal

Soligenix (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial - Digital Journal

Click here to get full coverage on Soligenix reports positive results from SGX945 trial for Behçet’s disease - Investing.com

Soligenix reports positive results from SGX945 trial for Behçet’s disease  Investing.com

Soligenix reports positive results from SGX945 trial for Behçet’s disease - Investing.com

Click here to get full coverage on Soligenix stock rises after positive Behçet’s Disease treatment data - Investing.com

Soligenix stock rises after positive Behçet’s Disease treatment data  Investing.com

Soligenix stock rises after positive Behçet’s Disease treatment data - Investing.com

Click here to get full coverage on Soligenix Inc.: An Unexpected Surge? - StocksToTrade

Soligenix Inc.: An Unexpected Surge?  StocksToTrade

Soligenix Inc.: An Unexpected Surge? - StocksToTrade

Click here to get full coverage on Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma  PR Newswire

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire

Click here to get full coverage on Soligenix closes $7.5 million public offering to extend cash runway - Investing.com

Soligenix closes $7.5 million public offering to extend cash runway  Investing.com

Soligenix closes $7.5 million public offering to extend cash runway - Investing.com

Click here to get full coverage on Soligenix Inc erwartet einen Verlust von 92 Cents pro Aktie - Earnings Preview - TradingView

Soligenix Inc erwartet einen Verlust von 92 Cents pro Aktie - Earnings Preview  TradingView

Soligenix Inc erwartet einen Verlust von 92 Cents pro Aktie - Earnings Preview - TradingView

Click here to get full coverage on Soligenix reports safety milestone in phase 3 CTCL treatment trial - Investing.com

Soligenix reports safety milestone in phase 3 CTCL treatment trial  Investing.com

Soligenix reports safety milestone in phase 3 CTCL treatment trial - Investing.com

Click here to get full coverage on Soligenix Announces Reverse Stock Split - PR Newswire

Soligenix Announces Reverse Stock Split  PR Newswire

Soligenix Announces Reverse Stock Split - PR Newswire

Click here to get full coverage on Soligenix Stock Shoots Up: Time to Dive In? - StocksToTrade

Soligenix Stock Shoots Up: Time to Dive In?  StocksToTrade

Soligenix Stock Shoots Up: Time to Dive In? - StocksToTrade

Click here to get full coverage on Soligenix Provides Shareholder Update on Rare Disease Pipeline - TipRanks

Soligenix Provides Shareholder Update on Rare Disease Pipeline  TipRanks

Soligenix Provides Shareholder Update on Rare Disease Pipeline - TipRanks

Click here to get full coverage on Soligenix reports positive results from psoriasis gel treatment trial - Investing.com

Soligenix reports positive results from psoriasis gel treatment trial  Investing.com

Soligenix reports positive results from psoriasis gel treatment trial - Investing.com

Click here to get full coverage on Soligenix Stock Soars: Is A Rebound Imminent? - StocksToTrade

Soligenix Stock Soars: Is A Rebound Imminent?  StocksToTrade

Soligenix Stock Soars: Is A Rebound Imminent? - StocksToTrade

Click here to get full coverage on Soligenix Stock Soars: What’s Next? - timothysykes.com

Soligenix Stock Soars: What’s Next?  timothysykes.com

SNGX

Price Chart

Key Statistics

Technicals

About SNGX

Latest News

SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Yahoo Finance

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - PR Newswire

SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Smartkarma

Advanced Charts

Top Gainers

Top Losers